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ABSTRACT We used a Saccharomyces cerevisiae genetic
system to detect the physical interaction of RAS and RAF
oncoproteins. We also observed interaction between RAS and
byr2, a protein kinase implicated as a mediator of the Schizo-
saccharomyces pombe rasl protein. Interaction with RAS re-
quired only the N-terminal domains of RAF or byr2 and was
disrupted by mutations in either the guanine nucleotide-
binding or effector-loop domains of RAS. We observed inter-
action between MEK (a kinase that phosphorylates mitogen-
activated protein kinases) and the catalytic domain of RAF.
RAS and MEK also interacted but only when RAF was
overexpressed.
The ras genes encode guanine nucleotide-binding proteins and
were first identified as oncogenes of acutely transforming
RNA tumor viruses (reviewed in ref. 1). Subsequently, mu-
tated RAS genes were found in many human tumors, providing
the first evidence of a common genetic defect in cancer. RAS
proteins participate in signal transduction pathways regulating
cell proliferation and differentiation, but their precise bio-
chemical functions are unknown. In mammals a variety of
extracellular agonists, such as insulin, platelet-derived growth
factor, and nerve growth factor, that act through protein-
tyrosine kinase receptors require RAS to exert their effects
(2-7). These agonists activate a set ofprotein-serine/threonine
kinases known as mitogen-activated protein kinases (MAP
kinases) reviewed in ref. 8. Activation of the MAP kinases by
these factors requires RAS (5-7), and RAS can itself activate
the MAP kinases in cells (5-7) and in complex cell-free
systems (9, 10).
The RAF oncogene is a strong candidate to encode a
downstream effector for RAS in mammalian cells. (i) Acti-
vated RAF can bypass the cellular requirement for RAS
function (3, 4). (ii) Dominant negative mutations ofRAF can
block transformation induced by RAS (11). (iii) Hyperphos-
phorylated RAF kinase is observed in cells treated with
agonists that activate RAS and in cells containing the acti-
vated RAS oncogene itself (7, 12). (iv) The RAF kinase can
activate the MAP kinase kinase known as MEK (13, 14).
RAS proteins are widely conserved in eukaryotes. In many
respects, the function of rasl, the Schizosaccharomyces
pombe RAS homolog, resembles the function of RAS in
vertebrates. Genetic evidence indicates that rasl activates
byr2, a protein kinase involved in sexual differentiation (15).
Overexpression ofbyr2 can bypass defects resulting from the
loss of rasl, and expression of the N-terminal putative
regulatory domain of byr2 appears to interfere with rasl
signaling. Genetic studies place byr2 upstream of byrl, a
homolog ofmammalian MEK and Saccharomyces cerevisiae
STE7 protein kinases, each of which is implicated in the
activation of protein kinases of the MAP kinase family
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(16-18). byr2 is itself a homolog of S. cerevisiae STEll (18),
which is required for phosphorylation and activation ofSTE7
(19, 20). Thus, byr2 appears to bear the same relationship to
byrl as does RAF to MEK.
We have sought evidence for interaction between RAS and
RAF and between RAS and byr2 by employing a genetic
method, known as the two-hybrid system, that detects phys-
ical interaction between protein domains when expressed as
fusion proteins in the yeast S. cerevisiae (21). Interacting
fusion proteins combine to form a DNA-binding and tran-
scriptional activation dimer that induces synthesis from a
,-galactosidase reporter gene in an appropriate host. This
approach has been tested and demonstrated for many pairs of
interacting proteins, including S. cerevisiae SNF1 and SNF4,
S. cerevisiae SNF1 and SIP1, mammalian Jun and Fos, and
S. cerevisiae RAS2 and its guanine nucleotide-exchange
protein, CDC25 (21-24).
MATERIAL AND METHODS
Yeast and Escherichia coli Strains, Media, and Genetic
Manipulations. The S. cerevisiae strain used as host for
,B-galactosidase expression studies was YPB2 (MATa ura3-52
his3-200 ade2-101 lys2-801 trpl-901 leu2-3,112 canr gal4-542
gal80-538 L YS2: :GALIUAS-LEU2TATA-HIS3 URA3::
GALJ17-mers(3xr.CYCJTATA-lacZ) and was kindly provided
by P. Bartel and S. Fields (State University of New York,
Stony Brook). Yeast cultures were grown in YPD (1% yeast
extract/2% peptone/2% glucose) or in synthetic minimal
medium (0.67% yeast nitrogen base/2% glucose with appro-
priate auxotrophic supplements). Standard genetic methods
were followed (25).
Nucleic Acid Manipulations and Analysis. Manipulation and
sequencing ofDNA were carried out by standard procedures
(26, 27). Polymerase chain reactions (PCRs) (28) were per-
formed under standard conditions using primers 25-35 nu-
cleotides in length. pMNCcraf (encoding wild-type RAF),
pMNC301 (encoding the dominant negative RAF mutant
[Trp375]RAF) (11), and pMNCBXB (encoding the activated
RAF mutant RAFAN1) (29) were gifts of Ulf Rapp. Plasmid
pAH-RAF was constructed by inserting a BamHI-Sac I
fragment isolated from pAD5RAF into the vector pRS423, a
HIS3-based 2-,um vector (30). pAD5RAF was obtained by
subcloning an Xho I-Sac I PCR-generated fragment contain-
ing the entire RAF sequence into pAD5 (18). pADH-HRAS
is a LEU2+ plasmid that expresses the human Ha-ras gene
from the ADHI promoter (31). The MAP kinase kinase MEK
was cloned from a rat embryonic cDNA library by PCR.
Plasmid pGBT9, provided by P. Bartel and S. Fields, is a
derivative ofpMA424-2 (21) and contains anADHI promoter
expressing the GAL4 DNA-binding domain (amino acids
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1-147) and the TRPI gene as a selectable marker. Plasmid
pGBT10 is a derivative of pGBT9, with the modified multi-
cloning site 5'-GAATTCGGATCCCATTTAAATGTCGAC-
3'. Plasmid pGADGH, a derivative of pGAD1 (32), was
provided by G. Hannon (Cold Spring Harbor Laboratory)
and contains the ADHI promoter expressing the GAL4
transcriptional activation domain (amino acids 768-881). At
the 3' end of this domain, the multicloning site ofpGAD1 was
replaced by the Spe I-Kpn I fragment of the multicloning site
ofplasmid pBluescript SK(-) (Stratagene). All inserts cloned
into these plasmids were obtained by PCR using appropriate
primers and templates. The various RAS mutants were
obtained by PCR or, in the case of [Ala35]HRAS, by the
Transformer mutagenesis kit (Clontech). The sequences of all
PCR products were verified by dideoxy sequencing.
P-Galactosidase Filter Assays. The filter assay with
5-bromo-4-chloro-3-indolyl /-D-galactopyranoside (Boeh-
ringer Mannheim) as substrate was essentially as described
(34) except that Whatman 50 paper was used instead of
nitrocellulose paper.
RESULTS
To test interactions between two proteins, they were ex-
pressed in yeast, fused at their N termini to either the
transcriptional activation domain (GAD) or the DNA-binding
domain (GBD) of the yeast GAL4 protein. The various
proteins tested in this way included the full length, point
mutants, or domains of the human HRAS, S. cerevisiae
RAS2, human RAF, rat MEK, and Sch. pombe byr2 proteins
(Fig. 1). S. cerevisiae SNF1 and SNF4 fusion proteins were
used as controls (21, 40). When jointly expressed as GAL4
fusion proteins, SNF1 and SNF4 induced ,B-galactosidase.
When expressed singly or in combination with other unre-
lated fusion proteins, ,B-galactosidase was not induced.
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Pairwise combinations of GBD and GAD protein fusions
were tested for their ability to interact by induction of
3-galactosidase activity when coexpressed in the appropriate
S. cerevisiae host (Table 1). In one series of experiments, a
pairwise combination was tested in a host that overexpressed
a third interacting protein (Table 2). ,B-Galactosidase activity
was assayed by the development of blue color in transformed
colonies cultured in the presence of 5-bromo-4-chloro-3-
indolyl 3-D-galactopyranoside, a chromogenic substrate. Re-
sults of a representative experiment are shown in Fig. 2.
Mammalian and S. cerevisiwe RAS Proteins Interact with
RAF. In the first series of experiments, we explored the
interaction of human HRAS with full-length human RAF.
Since the assay can detect interactions only when both
proteins translocate to the cell nucleus, we utilized
[Argl86]HRAS, which has arginine in place of the cysteine
residue of the CAAX motif. This motif, where A represents
an aliphatic amino acid, is required for the proper plasma
membrane localization ofRAS (41, 42). Host cells expressing
both RAF and [Arg186]HRAS synthesized 3-galactosidase
when either one of the proteins was fused to GBD and the
other to GAD (Table 1 and Fig. 2). Expression of both RAS
and RAF fusion proteins was essential. For example, ex-
pression of RAF fused to GAD and SNF4 fused to GBD did
not induce ,B-galactosidase synthesis. We did not observe
interaction between RAF and the wild-type HRAS, presum-
ably because the wild-type HRAS fusion protein failed to
localize to the nucleus. RAF also interacted with the S.
cerevisiae [Arg319]RAS2 mutant protein, which lacks the
CAAX motif.
We also examined the ability of other RAS mutants to
interact with RAF. The substitution of alanine for glycine at
position 22 of S. cerevisiae RAS2 disrupts the guanine nucle-
otide-binding domain (37, 38). The Gly22 -+ Ala mutation
introduced into [Arg31jRAS2 disrupts interaction with RAF.
The Thr35 -- Ala mutation introduced into [Argl86]HRAS
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FIG. 1. Schematic representation ofvarious
proteins tested in the two-hybrid system.[Arg186]HRAS and S. cerevisiae [Arg319]RAS2
contain single amino acid substitutions that
prevent their farnesylation and localization to
42 the plasma membrane. [Ala35]HRAS has a mu-
tation in the so-called effector loop (35, 36). The
Gly22 -- Ala mutation disrupts the guanine
FIA nucleotide binding of RAS2 (37, 38). RAFAN1
is a constitutively activated mutant ofRAF, and
lacks amino acids 26-302 (29). RAFAN2 con-
tains amino acids 375-648. RAFAC1 and
RAFAC2 contain amino acids 1-379 and 1-375,
respectively. [Trp375]RAF contains a point mu-
tation in the ATP-binding site of the kinase
N domain and is a dominant interfering form of
RAF (11, 39). byr2AC and byr2AN contain
amino acids 1-392 and 393-659, respectively.
The hatched boxes represent the catalytic do-
mains of the representative protein kinases.
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Table 1. Pairwise combinations of GBD protein fusions (listed at left) and GAD protein fusions (listed across the top)
(-Galactosidase induction, no. positive/no. scored
GBD fusions HRAS [Arg186]HRAS [Ala35,Arg186]HRAS RAF [Trp375]RAF MEK byr2 SNF1
HRAS 0/32 0/32 0/32
[Arg186]HRAS 0/48 56/56 0/56* 32/32 0/32
[Arg319]RAS2 48/48 24/24 0/24
[Ala22,Arg319]RAS2 - 0/48 0/24 0/24
RAF 0/24 96/96 0/48 0/48 160/160 0/48 0/32
RAFAN1 0/48 - - 96/96 0/12
RAFAC1 72/72 0/96 0/12
RAFAC2 48/48 0/48 - 0/12
[Trp375]RAF - 72/72 0/24
MEK 0/12 0/48* 56/56 0/48 0/36 0/24
byr2 16/16 - - - 0/8
byr2AC 16/16
byr2AN 0/24 -
SNF4 0/24 0/48 0/12 0/12 0/12 0/24 0/12 48/48
The values represent the number of independent transformed colonies that expressed detectable 3-galactosidase activity, divided by the total
number of independent transformants tested. -, Not tested. The proteins in the vertical column at left were fused to GBD. The proteins at the
top were fused with GAD. In most cases, several independently derived plasmids expressing the fusion proteins were tested.
*MEK-RAS interactions were observed when RAF was overexpressed (see text and Table 2).
disrupts the so-called "effector loop" through which RAS is
thought to interact with mammalian GTPase-activating protein
(GAP) and the S. cerevisiae adenylyl cyclase complex (35, 36,
43). The [Ala35,Arg186]HRAS mutant failed to interact with
RAF.
RAS Interacts with the N Terminus of RAF. To define the
region of RAF with which RAS interacts, we constructed
fusions of either the C-terminal or N-terminal domains of
RAF to GDB. We utilized two N-terminal deletions,
RAFAN1 and RAFAN2, and two C-terminal deletions,
RAFAC1 and RAFAC2. RAFAN1 is a mutant of RAF that
transforms cultured animal cells (29). We also utilized
[Trp375]RAF, in which the lysine of the ATP binding site of
the full-length protein is replaced with tryptophan, to deter-
mine whether the catalytic activity ofRAF was essential for
interaction with HRAS. The [Trp375]RAF protein is known to
interfere with wild-type RAS and RAF in mammalian cells
(11). [Arg186]HRAS interacts with the N terminus ofRAF and
with [Trp375]RAF. [Arg186]HRAS did not interact with the
C-terminal domain of RAF, yet that domain is capable of
interacting with MEK (see next section).
MEK Interacts with the C Terminus of RAF and Forms
Complexes with RAS in the Presence of RAF. RAF can
activate the MEK protein kinase (13, 14). We therefore
examined whether we could detect interaction between RAF
and MEK. The MEK gene was fused at its N terminus to
either GBD or GAD and then coexpressed with all the RAF
constructs depicted in Fig. 1. The results indicated that MEK
interacted with wild-type RAF and the RAF C-terminal
catalytic domain. MEK did not interact with the N-terminal
domain of RAF nor with [Trp375]RAF (Table 1). The inter-
Table 2. Interaction between RAS and MEK mediated by RAF
,B Galactosidase
GDB-[Arg186]HRAS GAD-MEK RAF induction
+ + + 16/16
+ + - 0/16
+ - + 0/8
+ + 0/8
_
- + 0/8
Host strains were transformed (+) or not (-) with plasmids
expressing the GBD-[Arg186]HRAS fusion, the GAD-MEK fusion,
or the full-length wild-type RAF protein (pAH-RAF). Individual
transformants were scored for ,-galactosidase production (no. pos-
itive/no. scored) by the filter assay described in Materials and
Methods.
action between RAF and MEK was weaker than that be-
tween RAF and RAS, as judged by the intensity of color
development.
We did not observe direct interaction between MEK and
RAS fusion proteins. However, MEK and RAS interact with
different domains ofRAF, and we reasoned that ifthe binding
of RAS to RAF did not interfere with the binding ofMEK to
RAF, the three might form a complex. To test this, we
expressed combinations of [Arg'86]HRAS and MEK fusion
proteins with or without wild-type RAF. Interaction between
[Arg186]HRAS and MEK was detected only when RAF was
also expressed (Table 2). This interaction was weaker than
that observed between RAF and MEK fusion proteins.
Sch. pombe byr2 Interacts with RAS. As we have discussed,
byr2 bears a similar relationship to byrl and RAS as does
RAF to MEK and RAS. We therefore examined the ability of
byr2 to interact with [Arg'86]HRAS. The results indicated
that byr2 interacted with [Arg186]HRAS expressed in S.
cerevisiae (Table 1). As in the case of RAF, the N-terminal
putative regulatory domain of byr2 interacted with HRAS.
byr2 did not interact with either RAF or MEK.
DISCUSSION
We have found evidence that RAS proteins form complexes
with certain protein kinases. Our conclusions depend entirely
upon the use of the two-hybrid system. Nevertheless, the
interactions we have observed are highly specific. We failed
to observe interactions between RAF and RAS proteins with
mutations that abolish RAS activity. Moreover, we have
tested interactions between 14 pairwise combinations of
known fusion proteins and RAF or [Arg186]HRAS and have
observed no false positives (data not shown). We have also
screened cDNA fusion libraries for genes encoding protein
domains capable of interacting with either [Arg186]HRAS or
RAF and have found positives at a frequency of <1 in 50,000
for RAF and <1 in 100,000 for [Arg'86]HRAS. Even allowing
for frameshift and other cloning artifacts, the occurrence of
false positives with our RAS and RAF fusion proteins must
be quite rare.
Our results strengthen the hypothesis that RAF is a down-
stream effector of RAS. More significantly, our results sug-
gest that RAS and RAF may interact directly. We cannot
conclude this with complete confidence because there may be
other factors within the yeast cell that bridge this interaction.
A more definitive proof would be the demonstration of the
coimmunoprecipitation of RAF and HRAS using purified
Cell Biology: Van Aelst et al.
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FIG. 2. RAF interacts with unprocessed HRAS. HRAS and RAF fused to either GBD (column B) orGAD (column A) were tested for possible
interaction by their induction of P-galactoside expression (blue color). In contrast to wild-type HRAS (row 1), the mutant [Arg'86]HRAS (row
2) fused to either GAD (Left) or GBD (Right) was able to interact with RAF. Rows 3 and 4 represent the corresponding negative controls: no
color developed unless both [Arg186]HRAS and RAF were expressed. [Arg186]HRAS (and also RAF) failed to interact with itself (rows 5 and
6). S. cerevisiae SNF1 and SNF4 were included as positive controls (row 7). Each patch represents an independent transformant.
components, but we have not as yet observed coprecipitation
from cells overexpressing both proteins. In fact, stable phys-
ical interactions between RAS and its known partners are
exceedingly difficult to demonstrate. We have never ob-
served coprecipitation between RAS and adenylyl cyclase,
its effector in S. cerevisiae (44, 45), or between RAS and
GAPs, proteins that accelerate GTP hydrolysis by RAS (46).
Stable interaction between RAS and CDC25 can be demon-
strated only with mutantRAS (47, 48). Similarly, crosslinking
experiments have been singularly ineffective (49). Thus, the
two-hybrid system may be particularly well suited for mon-
itoring weak protein-protein interactions of biological signif-
icance.
We have observed an interaction between human HRAS
and the Sch. pombe byr2 kinase. This interaction requires
only the N-terminal domain of byr2. The byr2 kinase resem-
bles mammalian RAF in its overall structure: both kinases are
large, with C-terminal catalytic domains. However, we ob-
serve essentially no primary structural homology in the
N-terminal putative regulatory domains of the two proteins.
In particular, byr2 does not contain a cysteine-rich domain
similar to the domain of RAF thought to participate in its
regulation (29). Nevertheless, our results confirm that the
relationship of byr2 to the signal transduction pathways of
Sch. pombe resembles the relationship of RAF to the signal
transduction pathways of vertebrates.
Ifbyr2 is an immediate downstream effector of rasl in Sch.
pombe, then Sch. pombe rasl is likely to have another
effector, because rasl is required to maintain normal cell
morphology in Sch. pombe, whereas byr2 is not (15). Thus,
in Sch. pombe, as in S. cerevisiae (50), there may be multiple
RAS effectors. We presume this to be true for metazoans as
well. It is possible, for example, that metazoans have ho-
mologs of byr2 that participate in RAS signal transduction
pathways. Also, RAF is only one member of a family of
related protein kinases (reviewed in ref. 51), and members of
this family may also be RAS effectors or effectors of other
members of the RAS superfamily.
We have confirmed an interaction between RAF and
MEK. This interaction requires the intact catalytic domain of
RAF but does not require its N-terminal domain. We pre-
sume that the interaction between RAF and MEK depends
upon the catalytic activity of RAF, since the Lys375s-) Trp
mutation of the putative ATP-binding site disrupts interac-
tion. The interaction of MEK requires the C terminus of
RAF, and the interaction ofRAS requires the N terminus of
RAF. Thus, a trimeric complex may form. Indeed, we
observed an interaction between RAS and MEK fusion
proteins in yeast, but only when we also coexpressed RAF
protein. We conclude that RAF can bridge the interaction of
RAS and MEK. Thus the association ofRAF with RAS may
also directly affect MEK (and even MAP kinase, through its
association with MEK) with respect to localization, activa-
tion, and access to substrates.
We do not know whether the interaction between RAS and
RAF depends upon RAS being in its GTP-bound state.
However, we failed to observe interaction when RAS had
mutations in its GDP/GTP-binding domain. Moreover, we
failed to observe interactions when RAS had mutations in its
effector loop. The particular mutation, Thr3s Ala, that
disrupts interaction with RAF also disrupts functional inter-
actions between HRAS and other known targets, including
mammalian GAP and the S. cerevisiae adenylyl cyclase
complex (35, 43). These results suggest that RAF forms a
complex with RAS when the latter is in its physiologically
active state.
Mammalian RAF is capable of interaction with S. cerevi-
siae RAS2. On the one hand this is somewhat surprising,
since the two molecules have been separated in evolution at
least since the development of metazoans. On the other hand,
mammalian HRAS is known to interact with the RAS2 targets
in S. cerevisiae (44, 52). Moreover, yeast RAS1, when
suitably modified at its C terminus, is capable oftransforming
mammalian cells (53). Thus, evolutionary drift in the RAS
pathway seems to result more from the presence or absence
of specific targets than from a gradual reshaping of the
functional interactions themselves.
We have shown that RAS interacts with RAF and with
byr2. It is known that RAS interacts directly with mammalian
GAP and with a variety of proteins that are members of the
GAPRAs family, such as NF1, IRA1, IRA2, and sarl (46, 54).
These proteins all down-regulate RAS function by acceler-
ating GTP hydrolysis. We do not know whether the GAPRAs
proteins bind to the same site on RAS as do byr2 and RAF.
However, the mutation at position 35 of HRAS seems to
disrupt interactions with both the protein kinases and the
GAPRAs proteins. It should not be surprising to find that
molecules that down-regulate RAS by accelerating its GTP-
ase activity, on the one hand, and effector molecules, on the
other, each bind to the same site on RAS, since all must
recognize RAS in its GTP-bound state.
The members of the GAPRAs family have detectable but
weak homology to each other, and it is difficult to define a
clear region of homology that is responsible for RAS inter-
action (54, 55). An even more difficult problem arises from
analysis of the primary sequences of byr2 and RAF. We
observe no homology between byr2 and RAF, outside oftheir
kinase domains, and no homology to the GAPRAS proteins.
Moreover, none of these proteins contain significant homol-
ogy to S. cerevisiae CAP or adenylyl cyclase, two potential
protein targets of RAS in that organism (33). By using the
two-hybrid system it should be straightforward to define the
RAS-interacting domains of RAF and byr2, and of GAP as
well, by mutagenesis. At that time it might become clearer
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whether a RAS-binding protein can be identified by its
primary sequence.
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